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Abstract
Background: In sub-Saharan Africa, early mortality is high following initiation of antiretroviral therapy (ART). We
investigated 6-month outcomes and factors associated with mortality in HIV-infected adults being assessed for ART
initiation and presenting with weight loss, chronic fever or diarrhea, and with negative TB sputum microscopy.
Methods: A prospective cohort study was conducted in Malawi, investigating mortality in relation to ART uptake,
microbiological findings and treatment of opportunistic infection (OIs), 6 months after meeting ART eligibility criteria.
Results: Of 469 consecutive adults eligible for ART, 74(16%) died within 6 months of enrolment, at a median of 41 days (IQR
20–81). 370(79%) started ART at a median time of 18 days (IQR 7–40) after enrolment. Six-month case-fatality rates were
higher in patients with OIs; 25/121(21%) in confirmed/clinical TB and 10/50(20%) with blood stream infection (BSI)
compared to 41/308(13%) in patients with no infection identified. Median TB treatment start was 27 days (IQR 17–65) after
enrolment and mortality [8 deaths (44%)] was significantly higher among 18 culture-positive patients with delayed TB
diagnosis compared to patients diagnosed clinically and treated promptly with subsequent culture confirmation [6/34
(18%);p= 0.04]. Adjusted multivariable analysis, excluding deaths in the first 21 days, showed weight loss .10%, low CD4
count, severe anemia, laboratory-only TB diagnosis, and not initiating ART to be independently associated with increased
risk of death.
Conclusions: Mortality remains high among chronically ill patients eligible for ART. Prompt initiation of ART is vital: more
than half of deaths were among patients who never started ART. Diagnostic and treatment delay for TB was strongly
associated with risk of death. More than half of deaths occurred without identification of a specific infection. ART
programmes need access to rapid point-of-care-diagnostic tools for OIs. The role of early empiric OI treatment in this
population requires further evaluation in clinical trials.
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Introduction
Mortality among patients initiating antiretroviral therapy (ART)
is high in the first months of treatment [1–3], especially in low
income countries. Between 8% and 26% of patients die in the first
year of ART [1,2]. Immunological and virological responses to
ART are similar in low and high income countries [1].
Causes of early death among patients on ART have been well
documented and include: tuberculosis (TB), sepsis, cryptococcal
meningitis (CM), malignancies, chronic diarrhea and wasting
syndrome [2–4]. Established risk factors include advanced
PLOS ONE | www.plosone.org 1 November 2012 | Volume 7 | Issue 11 | e48856
immunosuppression, WHO Clinical Stage 3 and 4, wasting,
anemia and payment for ART [1,3,5,6]. Conversely, prompt
initiation of ART can reduce mortality [2,3,5].
Deaths occurring between enrolment and actual initiation of
ART are less often reported, but are high. In two South African
cohorts, the numbers of deaths during this interval exceeded early
deaths after ART initiation [5,7]. Pulmonary and CNS infections,
notably TB, are the most common causes of serious opportunistic
infections (OIs) [8–13] in HIV-infected Africans. The etiology of
most fatal infections is determined only at autopsy [14].
Two previous studies in Malawi have shown that about half of
patients classified as WHO Stage 3 had unexplained weight loss,
chronic fever or chronic diarrhea [15]. Adults with these
symptoms have inferior early ART treatment outcomes compared
to those starting ART with other stage 3 diagnoses [16], most
likely relating at least in part to a high burden of active TB and/or
bloodstream infections (BSIs) that are difficult to diagnose in
resource-limited settings [17–24]. Once stabilised on treatment,
ART substantially reduces the risk of OIs, including TB. As well,
ART subsequently reduces all-cause mortality [25].
By the end of 2009, 271,105 HIV-infected individuals had been
registered on the national ART programme in Malawi and
Cotrimoxazole Preventive Therapy (CPT) had been widely
implemented [26]. In this context the aim of this study was to
investigate mortality 6 months after the intention to initiate ART,
in a cohort of ambulatory HIV-infected smear-negative Malawian
adults investigated for TB and serious BSIs [27]. The specific
objectives were to: i) describe 6-month outcomes in relation to
uptake of ART and treatment of serious infections (including TB)
ii) determine risk factors for death and iii) assess whether 6-month
outcomes were affected by different diagnostic processes.
Methods
Ethics Statement
This study received prior ethical approval from the National
Health Sciences Research Committee of Malawi and from the
Ethics Advisory Group of the International Union Against
Tuberculosis and Lung Disease. Both ethics committees approved
the consent form and consent procedure. All study participants
provided written informed consent.
Study Design
A prospective cohort study, conducted at two hospitals in
Malawi.
Study Setting
The study was carried out in the ART outpatient clinics at
Zomba Central Hospital and Thyolo District Hospital, serving 2
districts in the southern region of Malawi. Malawi has a high HIV
co-infection rate of 60–70% among TB patients [28] and an adult
HIV prevalence of approximately 12% [29]. The TB incidence in
Malawi in 2010 was estimated at 219/100,000 general population
[30]. It is the national policy in Malawi to prescribe CPT to all
HIV-infected persons. Patient enrolment took place from Febru-
ary to December 2010 and outcome data were obtained for the
period February 2010 to June 2011.
Study Participants
Patients enrolled into the study were ambulatory HIV-infected
adults ($15 years of age) who were intended to start ART and
presented with unexplained weight loss, chronic fever or chronic
diarrhea, with negative expectorated sputum smear microscopy
for TB [27]. Patients able to expectorate had sputum smear
microscopy either prior to, or during the screening process, on
three sputum specimens as per Malawi National TB Program
guidelines.
Study Interventions
The detailed methods, including laboratory methods and
procedures used in this study (to identify TB and BSIs) have been
described elsewhere [27]: in brief, on the day of enrolment all
patients had a symptom screen, blood culture (including TB),
cryptococcal antigen test (CrAg), a single induced sputum (IS)
specimen for TB microscopy and solid culture, full blood count
and CD4 lymphocyte count. Diagnostic test results were relayed
by study personnel to treating clinicians for treatment decisions.
Study Variables and Data Collection Instruments
Baseline characteristics of patients included: sex, age, weight
loss.10%, chronic fever, chronic diarrhea, lymphadenopathy,
oral candidiasis, Body Mass Index (BMI), CD4 count and
hemoglobin (Hb). BMI, CD4 and Hb were categorized using
conventional cut-off values [27]. Severe anemia was defined as Hb
,80 g/L (F) and ,90 g/L (M); moderate anemia as Hb 80–
109 g/L (F) & 90–119 g/L (M); mild or no anemia as Hb
$110 g/L (F) & $120 g/L (M). Diagnosed infections included:
TB diagnosed on clinical/radiological grounds either at enrol-
ment, or $21 days after enrolment, M. tuberculosis (MTB)
confirmed through smear or culture, or a BSI confirmed through
culture. The interval of 21 days from enrolment was chosen as
a reasonable time for sub-clinical TB to be unmasked with
reconstitution of the immune system and/or potentially more
intensive clinical surveillance and care during early ART
initiation.
Sources of Cohort Data
Diagnosed infections, treatment uptake and timing, and 6-
month outcomes were retrieved from patient files, TB registers
and ART databases. In cases where 6-month outcomes were not
reported, patients were traced to their homes. Information
obtained through tracing included verification of uptake and
timing of ART and treatment of BSIs in patients’ personal health
books, and/or date of death.
Data and Statistical Analysis
Baseline characteristics, diagnosed infections, uptake of treat-
ment and timing of treatment uptake or death were described with
proportions or medians (interquartile ranges [IQR]). Uptake of
treatment included: ART among all, TB treatment among TB
cases and antimicrobial treatment among BSI cases. Timing of
treatment uptake was defined as the interval between enrolment
and treatment start in days, where enrolment was the point at
which a patient was determined to be eligible for ART initiation.
Comparisons between groups were made using chi-square tests;
non-parametric independent sample median tests were used for
variables with non-normal distribution. Multivariable logistic
regression models were fitted with ‘‘death within 6 months of
enrolment’’ as the outcome variable to determine risk factors for
death. Covariates included baseline characteristics, diagnosis of an
infection and uptake and timing of treatment. In order to ensure
sufficient power, a minimum of 8 events per variable was defined
a priori as the criterion required for inclusion of a predictor variable
in the regression model [31]. All variables were simultaneously
entered in the model as the first step and tested for removal one by
one. The covariate ‘‘survived .21 days from enrolment/intention
to start ART’’ was also included in the model to address the
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immortal survival bias, which is a selection bias occurring in the early
observed effects where a cohort study design is being used to assess
a treatment, as individuals need to survive first to receive the
treatment [32]. The interval of 21 days was chosen, since in this
study population all patients who survived this interval should
have been started on ART when taking into account system delays
(e.g. initiation of TB treatment for TB cases, arranging appoint-
ments, transport issues, pre-ART counseling, etc.). A significance
level of 0.05 was set for all statistical testing.
Data and statistical analysis were conducted using IBM SPSS
Statistics 19 (IBM, Armonk, NY, USA).
Results
A total of 469 ART-eligible adults (58% female) were enrolled
in the study from February to December 2010. Twelve of the 555
patients referred for assessment of eligibility in the study, declined
to participate; 74 did not meet the inclusion criteria, as reported in
detail, previously [27].
Of all 469 patients included in the study, 35 did not have
a successful sputum induction; all of those had a negative TB
blood culture result, and 4 had a clinical TB diagnosis. Out of
these 35, at 6 months 20 were alive, 9 died and 6 were lost to
follow-up.
Figure 1 illustrates the number and proportion of patients
diagnosed with TB and/or BSIs and the number of individuals
who died as part of the total study cohort.
Within 6 months, a total of 74 (16%) patients had died. Deaths
occurred at a median of 41 days (IQR 20–81) from enrolment.
Among all deaths, 20 (27%) were within 3 weeks (21 days) and 62
(84%) within the first 3 months after study enrolment. Among
those who died within and after 21 days, the number and
proportion diagnosed with TB was 3 (15%) and 11 (20%); and
with BSIs, 6 (30%) and 4 (7%), respectively.
Cohort mortality at 6 months among patients with OIs was 423
deaths/1000 person-years, and 266 deaths/1000 person-years
among patients with no infection identified.
Table 1 shows 6-month outcomes by diagnosis and treatment
uptake. A total of 103 (22%) patients were diagnosed with TB
based on clinical/radiological grounds, including 34 (33%) where
the decision to treat as TB preceded laboratory confirmation of
TB. Ninety-two patients were clinically diagnosed with TB at
enrolment and another 11 patients $21 days after enrolment. A
further 18 (4%) MTB cases and 50 (11%) BSI cases were identified
solely through additional laboratory investigations provided by the
study. Mortality was highest among those who did not start ART
and/or appropriate treatment for other infections, varying from
34% among those with no identified infection and not yet on ART
to 100% among those with a laboratory confirmed BSI and not yet
on ART nor anti-microbial treatment.
Among the total cohort, 370 (79%) started ART at a median of
18 days (IQR 7–40) from enrolment. Mortality among those who
started ART and those who did not start ART was 34/370 (9%)
and 40/99 (40%), or 184 and 808 deaths/1000 person-years,
respectively (p = 0.001). In those who died, the median time to
death was 71 days (IQR 40–89) for those who started ART versus
26 days (IQR 13–41) for those who had not started ART
(p = 0.001).
Figure 1. STUDY COHORT.
doi:10.1371/journal.pone.0048856.g001
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Table 2 shows the characteristics of the adults who died
compared to those who survived 6 months from intention to start
ART. A greater proportion of adults who died had baseline weight
loss .10%, chronic diarrhea, severe anemia, a diagnosis of TB
based solely on laboratory investigations, and not yet started ART
(among all), not started TB treatment (among TB cases) or not
started antimicrobial treatment (among BSI cases) compared to
those who survived.
Tables 3 and 4 present the uptake and timing of treatment
(ART, TB and antimicrobial treatment). In addition, these tables
present 6-month mortality and timing of death by diagnosis of TB
(based on clinical/radiological grounds), TB confirmed on culture,
BSIs through laboratory investigations, or no infection identified.
Seventeen (17%) clinical/radiological TB cases died at a median
of 50 days (IQR 26–81) from enrolment: 1 died before treatment
commenced, 16 died on TB treatment (of whom 7 had also started
ART). Mortality among the TB cases diagnosed solely on
laboratory evidence (8/18) was significantly higher than that
among TB cases where the decision to treat was based on clinical/
radiological grounds (17/103), and among patients diagnosed
clinically with subsequent culture confirmation (6/34): (44% vs.
17% and 18%, respectively; p = 0.04). While there was no
difference in median time to ART initiation (p = 0.52), median
TB treatment start was 27 days later (p = 0.01) for those
individuals diagnosed solely using laboratory evidence compared
to those diagnosed on clinical grounds. Among the total group of
50 patients with confirmed BSIs, 10 (20%) died (7 before receiving
appropriate treatment), at a median of 20 days (IQR 12–41) from
enrolment. Deaths among individuals with BSI’s included; 5/29
non-typhoid Salmonella (NTS), 1/8 C. neoformans, 1/5 E. coli,
and 3/4 non-tuberculous mycobacteria (NTM). There were 10
BSI/TB (TB diagnosed on clinical/radiological grounded) co-
infections, of whom 2 (with NTS) died.
Of the remaining 308 individuals with no identified infection,
81% started ART at a median of 20 days (IQR 7–46). Forty-one
(13%) died at a median of 42 days (IQR 21–73) from enrolment of
whom 21/41 died without having started ART at a median of 23
days (IQR 14–50) from enrolment.
In multivariable analysis (Table 5) baseline weight loss .10%,
low CD4, severe anemia, being diagnosed with TB solely through
laboratory investigations and not initiating ART, were indepen-
dently associated with increased risk of death.
Patients needed to survive long enough to be able to start ART.
To assess the impact of potential immortal survival bias, the
association of not having started ART with mortality, with and
without adjusting for survival $21 days, was adjusted OR (aOR)
of 6.2 (95% CI 2.7–14.1) and aOR 10.5 (95% CI 5.1–21.9),
respectively.
Induced sputum microscopy and culture identified 18 patients
with MTB who did not already have a clinical diagnosis of TB, of
whom 8 started TB treatment (7 also started ART) and are known
to have survived 6 months. Among the 50 BSI cases, 34 started
ART and antimicrobial treatment and are known to have
survived.
Discussion
This study provides knowledge from typical programme settings
in Malawi and highlights that clinical decisions about antimicro-
bial treatment, especially TB treatment, are essential in order to
optimize survival, even with high-quality laboratory support
(where results are not available at point of care). Likewise, prompt
ART initiation regardless of infection status appears to be
associated with survival.
This study found that early mortality remains high among
chronically ill HIV-infected patients with non-specific WHO Stage
Table 1. Six-month outcomes by diagnosis and treatment uptake.
Diagnoses Treatment Uptake n LTF/TO# Alive Mortality
TB diagnosed on clinical grounds 103 23 (22%) 63 (61%) 17 (17%)
TB diagnosed at enrolment ART & TB Treatment 65 6 53 6 (9%)
TB Treatment only 25 12 4 9 (36%)
No ART & No TB Treatment 2 1 – 1 (50%)
TB diagnosed .20 days after enrolmentART & TB Treatment 10 3 6 1 (10%)
TB Treatment only 1 1 –
TB diagnosed through culture only 18 2 (11%) 8 (44%) 8 (44%)
ART & TB Treatment 11 7 4 (36%)
TB Treatment only 3 1 1 1 (33%)
No ART & No TB Treatment 4 1 3 (75%)
BSI identified through culture** 50 6 (12%) 34 (68%) 10 (20%)
ART & Antimicrobial Treatment 40 4 34 2 (5%)
ART only 4 2 2 (50%)
No ART & No Antimicrobial Treatment 6 6 (100%)
No infection identified 308 64 (21%) 203 (66%) 41 (13%)
ART 250 43 186 21 (8%)
No ART 58 21 17 20 (34%)
Totals** 469 94 (20%) 301 (64%) 74 (16%)
#LTF/TO = Lost to follow up/Transferred Out.
*clinical = clinical & radiology.
**10/50 BSI cases were also diagnosed with TB on clinical grounds and started on TB Treatment.
doi:10.1371/journal.pone.0048856.t001
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Table 2. Characteristics of ART-eligible adults who died within 6 months of intention to start ART versus those who are known to
be alive.
Adults who died within
6 months n=74
Adults who survived
6 months n=301 P-value
Baseline
characteristic
Sex, F 39 (53%) 177 (59%) 0.4
Median Age, in years (IQR) 35 (30–43) 36 (30–42) 0.9
Weight loss .10% 49 (66%) 143 (48%) 0.004
Chronic Fever 44 (59%) 183 (61%) 0.9
Chronic Diarrhea 34 (46%) 92 (31%) 0.01
Lymphadenopathy 27 (36%) 107 (36%) 0.9
Oral Candidiasis 24 (32%) 94 (31%) 0.9
BMI strata (kg/m2)*
Severe wasting; BMI,16.0 23 (31%) 74 (25%) 0.3
Moderate wasting; BMI 16.0–16.99 18 (24%) 59 (20%)
Mild or no wasting; BMI.17.0 33 (45%) 168 (56%)
CD4 strata (cells/mL)
CD4,50 22 (30%) 75 (25%) 0.7
CD4 50–199 35 (47%) 148 (49%)
CD4$200 17 (23%) 78 (26%)
Hemoglobin strata (g/L)
Severe anemia 33 (45%) 66 (22%) 0.001
Moderate anemia 26 (35%) 145 (48%)
Mild anemia or no anemia 15 (20%) 90 (30%)
TB and BSI’s TB diagnosed on clinical grounds at enrolment 16 (22%) 57 (19%) 0.6
TB diagnosed on clinical grounds
.20 days after enrolment
1 (1%) 6 (2%) 0.9
TB Laboratory confirmed only 8 (11%) 8 (3%) 0.005
BSI Laboratory confirmed 10 (14%) 34 (11%) 0.8
No infection 41 (55%) 203 (67%) 0.06
Treatment Started ART 34 (47%) 279 (93%) 0.001
Among those who started ART; Median
no of days from Enrolment to ART start (IQR)
17 (6–34) 20 (7–48) 0.7
Started TB Treatment (among TB cases) 21/25 (84%) 71/71 (100%) 0.004
Among those who started TB Treatment; Median
no of days from Enrolment to TB Treatment start (IQR)
7 (0–23) 0 (0–12) 0.1
Antimicrobial Treatment started (among BSI cases)** 2/10 (20%) 34/34 (100%) 0.001
*Conform WHO strata for BMI grading of severity of malnutrition.
**Incomplete data on BSI treatment start dates.
doi:10.1371/journal.pone.0048856.t002
Table 3. Case Management and Mortality of Individuals with a TB diagnosis.
Proportion
starting TB
Treatment
Median (IQR) days to
TB Treatment start % starting ART
Median (IQR) days
to ART start
Mortality 6 Months
post-enrolment
Median (IQR) days
enrolment-death
TB diagnosed on clinical
grounds at enrolment
90/92 0 (0–7) 65 (71%) 23 (14–42) 16 (17%) 46 (22–84)
TB diagnosed on clinical
grounds .20 days after
enrolment
11/11 47 (32–84) 9* (82%) 10 (1–15) 1 (9%) 58
MTB Laboratory confirmed
only
14/18 27 (17–65) 11 (61%) 9 (3–22) 8 (44%) 30 (26–85)
*TB diagnosed at a median of 29 days (IQR20–50) post ART initiation.
doi:10.1371/journal.pone.0048856.t003
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3 or 4 criteria for ART initiation, even with the benefit of more
intensive investigations for OIs than are usually afforded in
resource limited settings.
More than half of all deaths were among the minority (21%) of
patients who did not start ART, with the majority occurring within
one month of enrollment. Weight loss .10%, low CD4 count
(,200 and especially ,50) and severe anemia were also significant
risk factors for death.
Prompt initiation of ART in patients with suspected OIs is
supported by a number of randomized controlled trials [8,32–35]
that have shown benefit to early ART initiation (within 2 weeks) in
highly immunosuppressed patients, with the exception of those
with CNS infections where the risks of fatal immune reconstitution
inflammatory syndrome (IRIS) are high.
High mortality in this cohort of patients with advanced HIV
further supports earlier initiation of ART before WHO stage 3 or
4 illness have developed [3]. Closer follow-up for individuals with
HIV but not yet on ART, including regular CD4 count
assessments, will be key to identifying relatively fit individuals in
need of ART, and may be especially valuable in countries such as
Malawi that have high rates of potentially fatal OIs but limited
resources to diagnose OIs once established.
Initiation of ART and prompt TB treatment on clinical grounds
before culture confirmation were associated with increased
survival in this cohort. A recent study in South Africa found
reduced mortality among inpatients managed according to the
2007 World Health Organization guidelines for management of
severely ill HIV-infected patients (meeting expanded definitions
for suspected smear-negative TB) compared to the ‘‘standard’’
management [33]. The 2007 recommendations stress the need to
start TB treatment promptly without waiting for culture-confir-
mation.
In contrast, patients diagnosed solely through laboratory results
initiated TB treatment with a median one-month delay and had
substantially higher case-fatality rates. Our analysis suggests that
enhanced laboratory identification using solid culture media and
blood culture averted, at most, eight additional TB deaths
implying that solid TB culture, even if routinely available, may
offer only modest gains, a conclusion also reported from India
[37]. Prompt initiation of TB treatment would be better supported
through improved access to rapid point-of-care diagnostics for TB
but in their absence empiric TB treatment warrants careful
consideration, particularly among patients with the risk factors for
mortality observed in this study.
We could not specifically evaluate the impact on mortality of
time to initiation of ART after starting TB treatment. Recent
literature and guidelines support starting ART as soon as possible
or even at the same time as TB-treatment [33–36,38] but this was
not recommended in the Malawian national guidelines or made
operational at a national level at the time of this study. Although
75% of TB patients started ART, more than one third of TB
patients not initiating ART died, with half lost to follow-up, and
only a minority known to be alive at 6 months. Advanced clinical
disease, lack of coordination between ART and TB clinics, and
patient reluctance to be treated for both diseasessimultaneously are
likely contributing factors. Stigma and the fear of drug interactions
may also have influenced ART uptake among these TB patients
[28].
Among the small group of 10 patients with a diagnosis of TB
made after initiation of ART, mortality was low. These patients
started TB-treatment on average less than one month after ART
initiation, suggesting that most were unmasked due to TB immune
reconstitution inflammatory syndrome (IRIS). An observational
study from South Africa found that initiation of ART prior to TB
treatment was not associated with adverse outcomes [36]. This
suggests that ART initiation should not be delayed if TB cannot be
ruled out.
Table 4. Case Management and Mortality of Individuals with BSIs or No infection.
Proportion starting
Antimicrobial
Treatment* % started ART
Median (IQR) days to
ART start
Mortality 6 Months
post-enrolment
Median (IQR) days
enrolment-death
BSI** Laboratory confirmed 40/50 44 (88%) 15 (6–34) 10 (20%) 20 (12–41)
No infection identified at
enrolment
0/308*** 250 (81%) 20 (7–46) 41 (13%) 42 (21–73)
*Incomplete data on BSI treatment start
**10/50 were also diagnosed with TB on clinical grounds and started on TB Treatment.
***no data available on possible empiric antimicrobial use among patients with no infection diagnosed.
doi:10.1371/journal.pone.0048856.t004
Table 5. Risk Factors associated with 6-month mortality
among adults presenting for ART with unexplained weight
loss, chronic fever or diarrhea, but negative TB sputum
microscopy.
Risk Factor** Adjusted OR* (95% CI) P-value
Weight loss .10% 2.5 (1.2–5.1) 0.015
CD4 strata (cells/mL)
CD4,50 3.6 (1.3–10.1) 0.016
CD4 50–199 3.4 (1.3–8.9) 0.014
CD4$200 1
Hemoglobin strata (g/L)
#Severe anemia 2.9 (1.2–6.9) 0.019
#Moderate anemia 0.7 (0.3–1.7) 0.45
#Mild anemia or no anemia 1
MTB (Lab confirmed only) 4.3 (1.3–13.7) 0.001
No ART started 6.2 (2.7–14.1) 0.001
*Adjusted for baseline characteristics (sex, age, weight loss.10%, chronic fever,
chronic diarrhea, lymphadenopathy, oral candidiasis, BMI, CD4, Hb, occurrence
of an infection (TB diagnosed on clinical/radiological grounds at enrolment or
.20days after enrolment, MTB confirmed through laboratory investigations, or
a BSI confirmed through laboratory investigations) and uptake and timing of
treatment (ART among all, TB treatment among TB cases, antimicrobial
treatment (among BSI cases), in addition to survival of $21 days from
enrolment.
#See methods for definitions.
**Only significant associations are reported in this table.
doi:10.1371/journal.pone.0048856.t005
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Our study found a high mortality rate (9/41, excluding CM)
among patients with BSIs. NTS were especially common among
our cohort of chronically ill HIV-patients. Salmonella species have
also predominated in several other African studies, particularly in
high HIV prevalence settings [9,10]. In a cohort of patients with
NTS infections in Malawi in the pre-ART era, 98% of patients
tested were HIV-positive; the inpatient mortality rate was 47%
and recurrence rate 43% for the survivors [39]. Among our
patients, 21 of 29 patients with NTS survived, 3 were lost to follow
up; but all 24 others were initiated on ART. Major declines in
BSIs, and NTS, have been reported to coincide with ART scale-
up in both Uganda and Malawi [39,40]. Another Uganda study
[41] found septicemia less common in patients on ART especially
after one year on ART. Although still high, the mortality we
observed among patients with BSI is likely to have been mitigated
by the availability of ART.
A study of BSIs in Blantyre, Malawi [42] found that
mycobacterial and pneumococcal bacteremia and sepsis were
usually clinically obvious, but that NTS was not usually diagnosed
before blood culture results due to the nonspecific clinical signs.
Blood cultures are often not feasible in resource limited settings so
algorithms for empiric antimicrobial treatment need urgent
evaluation.
Limitations
Despite active tracing of patients the outcomes of 94 (20%) of
469 patients transferred out or lost to follow up are unknown.
Some of these patients have probably died [43] which would
increase the observed death rates. We were unable to capture
timing of loss to follow up as these data were taken from routine
programme records. Although, our risk factor analysis was
modeled to address the immortal survival bias, the results of this
time bias may overstate the beneficial effects of ART in this
prospective cohort study [32]. We did not assess the role played by
viral load as a determinant of mortality in this study, as access to
viral load testing was not available and is not routinely available in
clinical practice in Malawi.
Conclusion
Prompt initiation of ART is vital: more than half of all deaths
were among patients who never started ART, most dying within
one month of enrollment. ART needs to be seen as an urgent, life-
saving, treatment in patients with advanced HIV.
In this patient population intensified laboratory methods for TB
diagnosis may offer only modest gains in terms of mortality. In the
absence of practically available rapid diagnostics for TB or BSI in
resource-poor countries such Malawi, early empiric antimicrobial
therapy for TB and bloodstream infections such as NTS needs
further evaluation in clinical trials enrolling similar patients.
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